Literature DB >> 26774837

Atrial fibrillation and arterial hypertension: A common duet with dangerous consequences where the renin angiotensin-aldosterone system plays an important role.

Teresa Maria Seccia1, Brasilina Caroccia1, Maria Lorenza Muiesan2, Gian Paolo Rossi3.   

Abstract

Atrial fibrillation (AF) represents the most common sustained cardiac arrhythmia, as it affects 1%-2% of the general population and up to 15% of people over 80 years. High blood pressure, due to its high prevalence in the general population, is by far the most common condition associated with AF, although a variety of diseases, including valvular, coronary heart and metabolic diseases, are held to create the substrate favouring AF. Due to the concomitance of these conditions, it is quite challenging to dissect the precise role of high blood pressure in triggering/causing AF. Hence, even though the intimate association between high blood pressure and AF has been known for decades, the underlying mechanisms remain partially unknown. Accumulating evidences point to a major role of the renin-angiotensin-aldosterone system in inducing cardiac inflammation and fibrosis, and therefore electric and structural atrial and ventricular remodelling, with changes in ions and cell junctions leading to AF development. These evidences are herein reviewed with a particular emphasis to the role of the renin-angiotensin-system aldosterone system.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Aldosterone; Angiotensin; Atrial fibrillation; Cardiovascular risk; Hypertension

Mesh:

Year:  2016        PMID: 26774837     DOI: 10.1016/j.ijcard.2016.01.007

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  12 in total

Review 1.  Arterial Hypertension, Atrial Fibrillation, and Hyperaldosteronism: The Triple Trouble.

Authors:  Teresa M Seccia; Brasilina Caroccia; Gail K Adler; Giuseppe Maiolino; Maurizio Cesari; Gian Paolo Rossi
Journal:  Hypertension       Date:  2017-04       Impact factor: 10.190

Review 2.  New-onset atrial fibrillation: an update.

Authors:  Takeshi Omae; Eiichi Inada
Journal:  J Anesth       Date:  2018-03-09       Impact factor: 2.078

Review 3.  Arterial Hypertension, Aldosterone, and Atrial Fibrillation.

Authors:  Teresa M Seccia; Brasilina Caroccia; Giuseppe Maiolino; Maurizio Cesari; Gian Paolo Rossi
Journal:  Curr Hypertens Rep       Date:  2019-11-18       Impact factor: 5.369

Review 4.  Influence of Inflammation and Atherosclerosis in Atrial Fibrillation.

Authors:  Rose Mary Ferreira Lisboa da Silva
Journal:  Curr Atheroscler Rep       Date:  2017-01       Impact factor: 5.113

Review 5.  Invited review: hypertension and atrial fibrillation: epidemiology, pathophysiology, and implications for management.

Authors:  Jakub Gumprecht; Magdalena Domek; Gregory Y H Lip; Alena Shantsila
Journal:  J Hum Hypertens       Date:  2019-11-05       Impact factor: 3.012

6.  Association Between Bipolar Disorder or Schizophrenia and Oral Anticoagulation Use in Danish Adults With Incident or Prevalent Atrial Fibrillation.

Authors:  Morten Fenger-Grøn; Claus Høstrup Vestergaard; Anette Riisgaard Ribe; Søren Paaske Johnsen; Lars Frost; Annelli Sandbæk; Dimitry S Davydow
Journal:  JAMA Netw Open       Date:  2021-05-03

7.  Aldosterone and renin in cardiac patients referred for catheterization.

Authors:  Paul Erne; Andrea Müller; Gian Paolo Rossi; Burkhardt Seifert; Fabrice Stehlin; Maurice Redondo; Peter T Bauer; Richard Kobza; Therese J Resink; Dragana Radovanovic
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

8.  Relationship Between 25-Hydroxyvitamin D, Renin, and Collagen Remodeling Biomarkers in Atrial Fibrillation.

Authors:  Dimpi Patel; Aleksander Druck; Debra Hoppensteadt; Vinod Bansal; Yevgeniy Brailovsky; Mushabbar Syed; Jawed Fareed
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

9.  Incidence of Atrial Fibrillation and Mineralocorticoid Receptor Activity in Patients With Medically and Surgically Treated Primary Aldosteronism.

Authors:  Gregory L Hundemer; Gary C Curhan; Nicholas Yozamp; Molin Wang; Anand Vaidya
Journal:  JAMA Cardiol       Date:  2018-08-01       Impact factor: 14.676

Review 10.  Heart failure with preserved ejection fraction: insights from recent clinical researches.

Authors:  Mi-Na Kim; Seong-Mi Park
Journal:  Korean J Intern Med       Date:  2020-04-29       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.